Multiple sclerosis experts discuss data from four presentations on ozanimod, a disease modifying therapy that was presented at EAN 2022.
Germinal Center Activity Shows Potential As Target of Rituximab in NMOSD
Incorporating Technology and Virtual Reality in Parkinson Disease and Neurological Disorders: Jay Alberts, PhD
Potential Therapeutic Role of the Endocannabinoid System for Migraine
Differences in the Genetic Mutations of ALS: Anna Underhill, BS